The demo obtained the two its Most important endpoints, with semaglutide two.four mg demonstrating statistically substantial and excellent enhancements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH in comparison to placebo.oneVery good